A therapy made from the patient’s own cells
Autologous cellular therapy is an established treatment approach for highly debilitating diseases. BrainStorm applies it to neurodegeneration through NurOwn® - a proprietary, validated platform for producing MSC-NTF cells.
Science overview
- 01
Autologous cellular therapy
Why a therapy grown from the patient’s own bone marrow needs no donor matching and no immunosuppression.Read more - 02
MSC-NTF cells
How MSCs are differentiated to secrete high levels of neurotrophic factors - without genetic modification.Read more - 03
Cell production
Producing autologous MSC-NTF cells at the scale and quality needed to bring them to patients.Read more - 04
The exosome platform
A proprietary, allogeneic exosome platform derived from the same MSC-NTF cells - designed to deliver therapeutic proteins and nucleic acids.Read more - 05
Intellectual property
Worldwide rights to clinical development and commercialization of the NurOwn technology platform.Read more
Overview
What makes it different
BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treating neurodegenerative diseases.
Because the cells come from the patient, there is no donor matching and no immunosuppression - and because they are differentiated rather than genetically modified, the biology stays close to the body’s own repair machinery. BrainStorm has developed a targeted, innovative, proprietary and validated autologous cellular technology platform for the treatment of neurodegenerative diseases.
No donor matching
Cells originate from the patient’s own bone marrow.
Not genetically modified
MSCs are differentiated in culture, not edited.
Delivered to the CNS
Intrathecal injection places cells at the site of damage.
Recent publications
Full library- Restoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative MedicineJournal of the Academy of Public HealthView
- Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomesMuscle & NerveView
- Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisMultiple Sclerosis JournalView
- Erratum to: A randomized placebo-controlled Phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosisMuscle & NerveView
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.